

Data Sharing Statement

Wadden. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. *JAMA*. Published February 24, 2021. doi:10.1001/jama.2021.1831

Data

Data available: Yes

Data types: Deidentified participant data

How to access data: Data will be shared with bona fide researchers submitting a research proposal approved by the independent review board. Access request proposals can be found at novonordisk-trials.com. Data will be made available after research completion, and approval of the product and product use in the European Union and the USA. Individual participant data will be shared in data sets in a de identified/anonymized format.

When available: beginning date: 12-21-2030

Supporting Documents

Document types: None

Additional Information

Who can access the data: Bona fide researchers submitting a research proposal approved by the independent review board.

Types of analyses: For use as approved by the Independent Review Board according to the IRB Charter (see novonordisk-trials.com).

Mechanisms of data availability: Individual participant data will be shared in trial data sets in a de-identified/anonymized format using a specialized SAS data platform, following approval of a research proposal.

Any additional restrictions: N/A